ORAGENICS INC (OGEN) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, ORAGENICS INC's filing signal continuing negative.

Oragenics, Inc. is a development-stage biopharmaceutical company focused on creating pharmaceutical therapies delivered intranasally for neurological conditions and infectious diseases. Its lead product candidate, ONP-002, is a synthetic neurosteroid designed to treat mild traumatic brain injury (mTBI) by reducing swelling, oxidative stress, and inflammation. The drug is administered via a novel, breath-propelled intranasal device designed for direct and rapid access to the brain, aiming to minimize systemic exposure and side effects. The company has completed Phase 1 clinical trials for ONP-002 in Australia, demonstrating safety and tolerability, and plans to initiate Phase 2a trials in early 2026. Oragenics also strategically paused development of its COVID-19 vaccine program to concentrate resources on ONP-002.

The company currently has no products authorized for commercial distribution and therefore generates no revenue. Future revenue is anticipated from the potential commercialization of its product candidates, primarily ONP-002, through licensing agreements with industry partners or distributors.